1. Antiproliferative and proapoptotic activities of 4-hydroxybenzoic acid-based inhibitors of histone deacetylases
- Author
-
Carole Seidel, Mario Dicato, Marc Diederich, and Michael Schnekenburger
- Subjects
Cancer Research ,Cell cycle checkpoint ,Cell Survival ,Mitosis ,Parabens ,Antineoplastic Agents ,Apoptosis ,Histone Deacetylases ,chemistry.chemical_compound ,Inhibitory Concentration 50 ,4-Hydroxybenzoic acid ,medicine ,Humans ,Cell Proliferation ,Histone Acetyltransferases ,biology ,Cell Cycle ,Cancer ,Cell Differentiation ,U937 Cells ,medicine.disease ,Cell biology ,Histone Deacetylase Inhibitors ,Leukemia ,Histone ,Oncology ,chemistry ,Acetylation ,biology.protein ,MCF-7 Cells ,Drug Screening Assays, Antitumor ,K562 Cells - Abstract
Histone acetyltransferases (HATs) and histone deacetylases (HDACs) regulate cellular processes by modifying the acetylation status of many proteins. Pathologically altered HDAC activity contributes to cancer development and thus characterization of novel acetylation modulators is important for future anti-cancer therapies. In this study, we identified three novel 4-hydroxybenzoic acid derivatives as pan-HDAC inhibitors that increased protein acetylation levels, arrested cell cycle progression and triggered apoptotic cell death, without affecting viability of normal cells. Our data support the potential of 4-hydroxybenzoic acid derivatives as pan-HDAC inhibitors with anticancer properties.
- Published
- 2013